Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Affinity Health

Neither a doctor nor a teaching hospital

Research payments

$1,130,905

198 payments

Through program year 2025, Affinity Health is reported as receiving $1,130,905 in research payments, across 198 payments.

By program year

5 rows
Year Kind Amount Payments
2025 Research $13,526 2
2024 Research $87,444 6
2023 Research $481,507 67
2022 Research $361,490 85
2021 Research $186,938 38

Breakdown

Who paid Research payments · program years 2021–2025
  1. GlaxoSmithKline, LLC. $830,939 144 payments
  2. Eli Lilly and Company $130,283 6 payments
  3. Kiniksa Pharmaceuticals, Ltd. $85,633 17 payments
  4. Novartis Pharmaceuticals Corporation $42,005 6 payments
  5. Sun Pharmaceutical Industries Inc. $25,154 15 payments
  6. ACADIA Pharmaceuticals Inc $7,500 1 payment
  7. AbbVie, Inc. $4,258 3 payments
  8. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $2,935 1 payment
  9. Pfizer Inc. $2,198 5 payments
Studies the money was for Research payments · program years 2021–2025
  1. A Protocol to Collect Human Complement (Either Through Collection of S $554,845 44 payments
  2. Study name not reported $98,016 16 payments
  3. A Study of Daily Oral Orforglipron (Ly3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity Or Overweight at Increased Cardiovascular Risk (Achieve-4) $81,144 4 payments
  4. A Phase III, Randomized, Controlled, Observer-Blind Study to Demonstra $71,544 38 payments
  5. A Phase 1, Single-Blind, Safety, Reactogenicity, and Immunogenicity Tr $62,847 27 payments
  6. Phase 3, Double-Blind, Placebo-Controlled, Randomized Withdrawal Study with Open-Label Extension, to Assess the Efficacy and Safety of Rilonacept Treatment in Subjects with Recurrent Pericarditis (RHAPSODY) $57,779 10 payments
  7. A Study of Daily Oral Orforglipron (Ly3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity Or Overweight at Increased Cardiovascular Risk (Achieve-4) $49,139 2 payments
  8. A Randomized, Multicenter, Open-Label Trial Comparing the Effectiveness of An Inclisiran First Implementation Strategy to Usual Care on LDL Cholesterol (LDL-C) in Patients With Atherosclerotic Cardiovascular Disease and Elevated LDL-C (?70 MG/D $26,089 1 payment
  9. A Phase I/II, Randomised, Controlled Study to Assess the Safety, Effec $18,243 16 payments
  10. A randomized, multicenter, open-label trial comparing the effectiveness of an "inclisiran first" implementation strategy to usual care on LDL cholesterol (LDL-C) in patients with atherosclerotic cardiovascular disease and elevated LDL-C (70 mg/dL) despite receiving maximally tolerated statin therapy (VICTORION-INITIATE) $14,694 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record